Hemispherx Biopharma (HEB) Stock: Running On Ampligen News

Hemespherx BioPharma HEB Stock News

Hemispherx BioPharma, Inc (NYSEAMERICAN: HEB) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced an update surrounding the commercialization of its Ampligen product, exciting investors and sending the stock on a run for the top. Today, we’ll talk about:

  • The update;
  • what we’re seeing from HEB stock as a result; and
  • what we’ll be watching for ahead.

HEB Announces Ampligen Update

As mentioned above, Hemispherx Biopharma is having a great day in the market today after the comapny announced an update regarding Ampligen. The update came by way of press release early this morning.

In the release, HEB announced impressive results from a blood-based, real-time diagnostic test out of Stanford University. The results demonstrate an ability to identify moderate to severe ME/CFS patients from normal controls.

At the moment, there is no specific ME/CFS laboratory diagnostic assay. As a result, diagnosis is based on disease exclusion.

In a statement, Thomas K. Equels, CEO at HEB, had the following to offer:

This is a potentially landmark study on two fronts. First, ME/CFS has been thought of by many as a psychological disorder without a physical basis, leaving ME/CFS sufferers with the pain of the disease and a sense of hopelessness. This diagnostic creates a new paradigm of hope for therapy for those with the disease.

Second, a validated blood-based method to diagnose ME/CFS would have a profound impact on how it is studied and treated by clearly identifying whether a subject has the disease. We look forward to the day when we can incorporate such a diagnostic platform into our own clinical testing for ME/CFS. We have the only late-stage drug candidate in the FDA pipeline and have been asked to do a confirmatory clinical trial. If properly validated with larger numbers of subjects, a blood-based diagnostic for ME/CFS should help in achieving regulatory approval.

What We’re Seeing From The Stock 

One of the first lessons that we learn when we start to work in the market is that the news leads to moves. When it comes to Hemispherx Biopharma, the news proved to be overwhelmingly positive.

Not only did the company announced a potential way to test for ME/CFS, having a diagnostic tool will help the company in its effort to bring Ampligen to market in the United States for this indication. So, it’s not surprising to see that excited investors are pushing the stock for the top.

As is just about always the case, our partners at Trade Ideas were the first to alert us to the movement. At the moment (9:21), HEB is trading at $0.19 per share after a gain of $0.023 per share or 13.27% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on HEB. In particular, we’re interested in following the story surrounding the company’s continued work with regard to Ampligen. Nonetheless, we’ll follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required


Please enter your comment!
Please enter your name here